{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:44:53Z","timestamp":1794865493871,"version":"4.9.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"PaTHway trial","award":["NCT04701203"],"award-info":[{"award-number":["NCT04701203"]}]},{"name":"Ascendis Pharma Bone Diseases"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The PaTHway clinical trial demonstrated sustained efficacy, safety, and tolerability of daily palopegteriparatide in the treatment of adults with hypoparathyroidism. Palopegteriparatide treatment was also associated with improvements in estimated glomerular filtration rate (eGFR) over 52\u00a0wk in a post hoc analysis, prompting further exploration of palopegteriparatide in the preservation of renal function. The current post hoc analysis evaluated the impact of palopegteriparatide treatment on renal function in adults with hypoparathyroidism through Week 104; as with prior analysis, changes in renal function were assessed using eGFR. At Week 104, 93% (76\/82) of participants remained in the open-label extension. Of those, 82% had albumin-adjusted serum calcium levels in the normal range (8.3-10.6\u00a0mg\/dL), 97% were independent from conventional therapy (\u2264600\u00a0mg\/d of elemental calcium and no active vitamin D). Mean (SD) serum phosphate (3.5 (0.7) mg\/dL) and albumin-adjusted calcium \u00d7 phosphate product (30.7(5.1) mg2\/dL2) levels were also within normal ranges. Palopegteriparatide treatment resulted in a mean (SD) increase in eGFR of 8.9 (11.0) mL\/min\/1.73m2 (p &amp;lt; .0001) from baseline to Week 52, which was sustained through Week 104, where it was 77.8 (14.8) mL\/min\/1.73\u00a0m2 with a mean (SD) change from baseline of 9.0 (10.3) mL\/min\/1.73\u00a0m2 (p\u2009&amp;lt;\u2009.0001). By Week 104, 45% and 34% of participants had an increase in eGFR of \u22655\u00a0mL\/min\/1.73\u00a0m2 and \u226510\u00a0mL\/min\/1.73\u00a0m2, respectively. Palopegteriparatide treatment normalized mean (SD) 24-h urine calcium within 26 wk and maintained levels below 250\u00a0mg\/d through Week 104 (158.8 (90.5) mg\/24\u00a0h). Most treatment-emergent adverse events were mild or moderate; no new safety signals or cases of treatment-related nephrolithiasis were reported. These findings demonstrate sustained renal safety of palopegteriparatide and suggest that PTH replacement therapy with palopegteriparatide preserves and may improve renal function in adults with chronic hypoparathyroidism after 104 wk of treatment.<\/jats:p>","DOI":"10.1093\/jbmr\/zjag085","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:33:18Z","timestamp":1779190398000},"page":"922-933","source":"Crossref","is-referenced-by-count":4,"title":["Sustained improvement in renal function with palopegteriparatide in adults with chronic hypoparathyroidism: 2-year results from the phase 3 PaTHway-trial"],"prefix":"10.1093","volume":"41","author":[{"given":"Lars","family":"Rejnmark","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine and Endocrinology, Aarhus University Hospital , Aarhus , 8200 Aarhus N,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8392-8004","authenticated-orcid":false,"given":"Elvira O","family":"Gosmanova","sequence":"additional","affiliation":[{"name":"Nephrology Section, Department of Medicine, Albany Stratton VA Medical Center , Albany, NY 12008,","place":["United States"]},{"name":"Division of Nephrology and Hypertension, Department of Medicine, Albany Medical College , Albany, NY 12208,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3733-8956","authenticated-orcid":false,"given":"Aliya A","family":"Khan","sequence":"additional","affiliation":[{"name":"Divisions Endocrinology and Metabolism and Geriatrics, Department of Medicine, McMaster University , Hamilton, ON , L8S 4L8,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Sprague","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, NorthShore University Health System , Evanston, IL 60201,","place":["United States"]},{"name":"Department of Medicine, Pritzker School of Medicine, University of Chicago , Chicago, IL 60607,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores M","family":"Shoback","sequence":"additional","affiliation":[{"name":"Endocrine Research Unit, University of California San Francisco Medical Center , San Francisco, CA 94143,","place":["United States"]},{"name":"Department of Internal Medicine, San Francisco VA Medical Center , San Francisco, CA 94121,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Kohlmeier","sequence":"additional","affiliation":[{"name":"Spokane Osteoporosis and Endocrinology, Arthritis Northwest Research Center , Spokane, WA 99223,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mishaela R","family":"Rubin","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Columbia University , New York, NY 10032,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1143-4926","authenticated-orcid":false,"given":"Andrea","family":"Palermo","sequence":"additional","affiliation":[{"name":"Endocrinology and Diabetes Unit, Campus Bio-Medico University of Rome , Roma , 00128,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0483-8594","authenticated-orcid":false,"given":"Peter","family":"Schwarz","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Rigshospitalet , Copenhagen , 2100,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9623-962X","authenticated-orcid":false,"given":"Claudia","family":"Gagnon","sequence":"additional","affiliation":[{"name":"Facult\u00e9 de m\u00e9decine, Universit\u00e9 Laval , Quebec City, QC , G1V 0A6,","place":["Canada"]},{"name":"Centre de recherche du CHU de Qu\u00e9bec-Universit\u00e9 Laval , Quebec, QC , G1V 4G2,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Tsourdi","sequence":"additional","affiliation":[{"name":"Department of Medicine III and Center for Healthy Aging, Dresden University of Technology , Dresden , 01307,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Endocrine Center, Toranomon Hospital Kajigaya , Kawasaki , 213-8587,","place":["Japan"]},{"name":"Okinaka Memorial Institute for Medical Research , Minato-Ku, Tokyo , 105-8470,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5722-115X","authenticated-orcid":false,"given":"Noriko","family":"Makita","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology, The University of Tokyo Hospital , Tokyo , 113-8655,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Imanishi","sequence":"additional","affiliation":[{"name":"Department of Clinical Medical Science, Osaka Metropolitan University Graduate School of Medicine , Osaka , 545-8585,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Gittoes","sequence":"additional","affiliation":[{"name":"Centre for Endocrinology, Diabetes and Metabolism, Queen Elizabeth Hospital Birmingham , Birmingham , B15 2GW,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan J","family":"D\u00edez","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Hospital Universitario Puerta de Hierro Majadahonda , Majadahonda , 28220,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Prot-Bertoye","sequence":"additional","affiliation":[{"name":"Service de Physiologie-Explorations Fonctionnelles, H\u00f4pital Europ\u00e9en Georges Pompidou , Paris , 75015,","place":["France"]},{"name":"Centre de R\u00e9f\u00e9rence des Maladies Rares du Calcium et du Phosphate, Assistance Publique H\u00f4pitaux de Paris , Paris , 75015,","place":["France"]},{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris , 75006,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryant","family":"Lai","sequence":"additional","affiliation":[{"name":"Ascendis Pharma, LLC , Palo Alto, CA 94304 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Zhao","sequence":"additional","affiliation":[{"name":"Ascendis Pharma, LLC , Palo Alto, CA 94304 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Ukena","sequence":"additional","affiliation":[{"name":"Ascendis Pharma, LLC , Palo Alto, CA 94304 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Makara","sequence":"additional","affiliation":[{"name":"Ascendis Pharma, LLC , Palo Alto, CA 94304 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher T","family":"Sibley","sequence":"additional","affiliation":[{"name":"Ascendis Pharma, LLC , Palo Alto, CA 94304 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1801-5289","authenticated-orcid":false,"given":"Aimee D","family":"Shu","sequence":"additional","affiliation":[{"name":"Ascendis Pharma, LLC , Palo Alto, CA 94304 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"issue":"6","key":"2026082903271127500_ref1","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1007\/s12325-024-02843-8","article-title":"Palopegteriparatide treatment improves renal function in adults with chronic hypoparathyroidism: 1-year results from the phase 3 PaTHway trial","volume":"41","author":"Rejnmark","year":"2024","journal-title":"Adv Ther"},{"issue":"6","key":"2026082903271127500_ref2","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.kint.2016.06.041","article-title":"Parathyroid hormone metabolism and signaling in health and chronic kidney disease","volume":"90","author":"Evenepoel","year":"2016","journal-title":"Kidney Int"},{"issue":"11","key":"2026082903271127500_ref3","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1007\/s12325-022-02292-1","article-title":"Five-year estimated glomerular filtration rate in adults with chronic hypoparathyroidism treated with rhPTH(1-84): a retrospective cohort study","volume":"39","author":"Ayodele","year":"2022","journal-title":"Adv Ther"},{"issue":"12 Pt 1","key":"2026082903271127500_ref4","first-page":"1356","article-title":"Effects of PTH(1-34) on blood pressure, renal function, and hormones in essential hypertension: the altered pattern of reactivity may counteract raised blood pressure","volume":"10","author":"Jespersen","year":"1997","journal-title":"Am J Hypertens"},{"issue":"2","key":"2026082903271127500_ref5","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11154-020-09613-1","article-title":"Renal complications in patients with chronic hypoparathyroidism on conventional therapy: a systematic literature review: renal disease in chronic hypoparathyroidism","volume":"22","author":"Gosmanova","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"issue":"4","key":"2026082903271127500_ref6","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1007\/s12325-021-01658-1","article-title":"Risk of chronic kidney disease and estimated glomerular filtration rate decline in patients with chronic hypoparathyroidism: a retrospective cohort study","volume":"38","author":"","year":"2021","journal-title":"Adv Ther"},{"issue":"12","key":"2026082903271127500_ref7","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1210\/jc.2012-1808","article-title":"Long-term follow-up of patients with hypoparathyroidism","volume":"97","author":"Mitchell","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026082903271127500_ref8","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s40618-020-01442-y","article-title":"Burden of illness in patients with chronic hypoparathyroidism not adequately controlled with conventional therapy: a Belgium and the Netherlands survey","volume":"44","author":"Hamdy","year":"2021","journal-title":"J Endocrinol Investig"},{"issue":"1","key":"2026082903271127500_ref9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/ki.2015.76","article-title":"What is nephrocalcinosis?","volume":"88","author":"Shavit","year":"2015","journal-title":"Kidney Int"},{"issue":"10","key":"2026082903271127500_ref10","doi-asserted-by":"crossref","first-page":"e3557","DOI":"10.1210\/clinem\/dgaa490","article-title":"Five-year estimated glomerular filtration rate in patients with hypoparathyroidism treated with and without rhPTH(1-84)","volume":"105","author":"Chen","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026082903271127500_ref11","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/jbmr.4016","article-title":"A randomized double-blind placebo-controlled first-In-human phase 1 trial of TransCon PTH in healthy adults","volume":"35","author":"Karpf","year":"2020","journal-title":"J Bone Miner Res"},{"key":"2026082903271127500_ref12","volume-title":"Australian Product Information: Yorvipath (palopegteriparatide) solution for injection","author":"TGA","year":"2025"},{"key":"2026082903271127500_ref13","volume-title":"FDA approves new drug for hypoparathyroidism, a rare disorder","author":"FDA","year":"2024"},{"key":"2026082903271127500_ref14","volume-title":"Yorvipath (palopegteriparatide)","author":"EMA","year":"2023"},{"key":"2026082903271127500_ref15","volume-title":"Public Assessment Report - Yorvipath (palopegteriparatide)","author":"MHRA","year":"2024"},{"key":"2026082903271127500_ref16","volume-title":"The Israeli Drug Registry - Yorvipath","author":"MHI","year":"2025"},{"key":"2026082903271127500_ref17","volume-title":"Teijin Pharma Receives Manufacturing and Marketing Approval in Japan for YORVIPATH as the Treatment for Hypoparathyroidism","year":"2025"},{"issue":"1","key":"2026082903271127500_ref18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/jbmr.4726","article-title":"Efficacy and safety of parathyroid hormone replacement with TransCon PTH in hypoparathyroidism: 26-week results from the phase 3 PaTHway trial","volume":"38","author":"Khan","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2026082903271127500_ref19","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.surg.2024.05.005","article-title":"Long-term kidney outcomes in patients with permanent hypoparathyroidism after total thyroidectomy for benign disease: a population-based study","volume":"176","author":"Luk","year":"2024","journal-title":"Surgery"},{"issue":"3","key":"2026082903271127500_ref20","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/s12020-025-04187-x","article-title":"Impaired renal function in patients with permanent hypoparathyroidism after thyroidectomy: analysis of a nationwide cohort in Spain","volume":"88","author":"D\u00edez","year":"2025","journal-title":"Endocrine"},{"issue":"4","key":"2026082903271127500_ref21","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate","volume":"145","author":"Levey","year":"2006","journal-title":"Ann Intern Med"},{"issue":"9","key":"2026082903271127500_ref22","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2019010007","article-title":"GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials","volume":"30","author":"Inker","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"2026082903271127500_ref23","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1681\/ASN.2015040341","article-title":"Change in measured GFR versus eGFR and CKD outcomes","volume":"27","author":"Ku","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"2026082903271127500_ref24","doi-asserted-by":"publisher","first-page":"e14326","DOI":"10.1111\/ctr.14326","article-title":"Defining a minimal clinically meaningful difference in 12-month estimated glomerular filtration rate for clinical trials in deceased donor kidney transplantation","volume":"35","author":"Mayne","year":"2021","journal-title":"Clin Transpl"},{"issue":"6","key":"2026082903271127500_ref25","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1053\/j.ajkd.2014.08.018","article-title":"GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials","volume":"64","author":"Lambers Heerspink","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"2026082903271127500_ref26","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.2337\/dc11-2189","article-title":"Glomerular hyperfiltration and renal disease progression in type 2 diabetes","volume":"35","author":"Ruggenenti","year":"2012","journal-title":"Diabetes Care"},{"issue":"7","key":"2026082903271127500_ref27","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/s41591-023-02418-0","article-title":"A meta-analysis of GFR slope as a surrogate endpoint for kidney failure","volume":"29","author":"Inker","year":"2023","journal-title":"Nat Med"},{"key":"2026082903271127500_ref28","volume-title":"Qualification Opinion for GFR Slope as a Validated Surrogate Endpoint for RCT in CKD","author":"CHMP","year":"2023"},{"key":"2026082903271127500_ref29","first-page":"419","article-title":"Ageing and the glomerular filtration rate: truths and consequences","volume":"120","author":"Glassock","year":"2009","journal-title":"Trans Am Clin Climatol Assoc"},{"issue":"1","key":"2026082903271127500_ref30","doi-asserted-by":"publisher","first-page":"10165","DOI":"10.1038\/s41598-021-89442-7","article-title":"Distribution of estimated glomerular filtration rate and determinants of its age dependent loss in a German population-based study","volume":"11","author":"Waas","year":"2021","journal-title":"Sci Rep"},{"issue":"11","key":"2026082903271127500_ref31","doi-asserted-by":"crossref","first-page":"e089783","DOI":"10.1136\/bmjopen-2024-089783","article-title":"Rate of decline in kidney function with age: a systematic review","volume":"14","author":"Guppy","year":"2024","journal-title":"BMJ Open"},{"key":"2026082903271127500_ref32","doi-asserted-by":"crossref","first-page":"156335","DOI":"10.1016\/j.metabol.2025.156335","article-title":"Best practice recommendations for the diagnosis and management of hypoparathyroidism","volume":"171","author":"Khan","year":"2025","journal-title":"Metabolism"},{"issue":"19","key":"2026082903271127500_ref33","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"2026082903271127500_ref34","first-page":"98","article-title":"Renal function during calcitriol therapy in chronic renal failure","volume":"33","author":"Bertoli","year":"1990","journal-title":"Clin Nephrol"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjag085\/68359552\/zjag085.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/41\/9\/922\/68359552\/zjag085.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/41\/9\/922\/68359552\/zjag085.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:27:25Z","timestamp":1787988445000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/41\/9\/922\/8689972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5,21]]},"published-print":{"date-parts":[[2026,8,21]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjag085","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,5,21]]}}}